T-Cell response to orally administered antigens and its role in the treatment of autoimmune diseases

Chemical Immunology

Volumn 71, Issue , 1998, Pages 139-160

  Liu, L M ^a   Weiner, H L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHOLINERGIC RECEPTOR; COLLAGEN TYPE 2; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN F(AB) FRAGMENT; INSULIN; INTERLEUKIN 2; MYELIN; VITRONECTIN;

ANTIGEN PRESENTATION; ARTHRITIS; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CLONAL ANERGY; COLITIS; DIABETES MELLITUS; DOSE RESPONSE; EXPRESSION VECTOR; HELPER CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INTRANASAL DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PEYER PATCH; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; UVEITIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS; AUTOIMMUNE DISEASES; HUMANS; PEYER'S PATCHES; T-LYMPHOCYTES;

EID: 0031785912     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Wells HG: Studies on the chemistry of anaphylaxis. III. Experiments with isolated proteins, especially those of the hen's egg. J Infect Dis 1911;8:147-171.
2. Chase M: Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc Soc Exp Biol Med 1946;61:257-259.
3. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO: Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding. J Immunol 1994;152:4663-4670.
4. Mowat AM: The regulation of immune responses to dietary protein antigens. Immunol Today 1987; 8:93-98.
5. Weiner HL: Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343.
6. Husby S, Jensenius JC, Svehag S-E: Passage of undergraded dietary antigen into the blood of healthy adults: Further characterization of the kinetics of uptake and the size distribution of the antigen. Scand J Immunol 1986;24:447-452.
7. Bruce MG, Ferguson A: Oral tolerance to ovalbumin in mice: Studies of chemically modified and biologically filtered antigen. Immunology 1986;57:627-630.
8. Bruce MG, Ferguson A: Oral tolerance produced by gut-processed antigen. Adv Exp Med Biol 1987;216A:721-731.
9. Michael J: The role of digestive enzymes in orally induced immune tolerance. Immunol Invest 1989; 18:1049-1054.
10. Hanson DG, Roy MJ, Miller SD, Seldman EG, Thomas MJ, Sanderson IR, Udall JN, Ely I, Green GM: Endopeptidase inhibition and intestinal antigen processing in mice. Regional Immunol 1993; 5:85-93.
11. Peng HJ, Turner MW, Strobel S: The generation of a 'tolerogen' after the ingestion of ovalbumin is time-dependent and unrelated to serum levels of immunoreactive antigen. Clin Exp Immunol 1990;81:510-515.
12. Strobel S: Neonatal oral tolerance. Oral tolerance: Mechanisms and applications. Ann NY Acad Sci 1996;778:88-102.
13. Richman LK, Graeff AS, Strober W: Antigen presentation by macrophage-enriched cells from the mouse Peyer's patch. Cell Immunol 1981;62:110-118.
14. Liu LM, MacPherson GG: Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J Exp Med 1993;177:1299-1307.
15. Bland PW, Warren LG: Antigen presentation by epithelial cells of the rat small intestine. II. Selective induction of suppressor T cells. Immunology 1986;58:9-14.
16. Mayer L, Shlien R: Evidence for function of Ia molecules on gut epithelial cells in man. J Exp Med 1987;166:1471-1483.
17. Galliaerde V, Desvignes C, Peyron E, Kaiserlian D: Oral tolerance to haptens: Intestinal epithelial cells from 2,4-dinitrochlorobenzene-fed mice inhibit hapten-specific T cell activation in vitro. Eur J Immunol 1995;25:1385-1390.
18. Harper HM, Cochrane L, Williams NA: The role of small intestinal antigen-presenting cells in the induction of T-cell reactivity to soluble protein antigens: Association between aberrant presentation in the lamina propria and oral tolerance. Immunology 1996;89:449-456.
19. Daynes R, Araneo B, Dowell T, Huang K, Dudley D: Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990;171:979-996.
20. 2 cells in murine Peyer's patches by oral immunization. Int Immunol 1992;4:433-445.
21. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996;383: 787-793.
22. Gonnella PA, Chen Y, Inobe J-i, Quartulli M, Weiner HL: In situ immune response in gut associated lymphoid tissue (GALT) following oral antigen in TcR mice. J Immunol 1998;160:4708-4718.
23. Liu L, Rich BE, Inobe J-i, Chen W, Weiner HL: Induction of T helper 2 cell differentiation in the primary immune response: Dendritic cells isolated from adherent cell culture treated with interleukin-10 prime naive CD4+ T cells to secrete interleukin-4. Int Immunol 1998; in press.
24. DeSmedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M: Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997;27:1229-1235.
25. 2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997;159:28-35.
26. Everson MP, Lemak DG, McGhee JR, Beagley KW: FACS-sorted spleen and Peyer's patch dendritic cells induce different responses in Th0 clones. Adv Exp Med Biol 1997;417:357-362.
27. Viney JL, O'Malley JM, Williamson E, Fanger N, Mowat AM: Expanding dendritic cell in vivo enhances the induction of oral tolerance: DC may act as tolerogenic antigen presenting cells. FASEB 1998;12:A3469.
28. Kuchroo V, Prabhu Das M, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules differentially activate the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707-718.
29. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke K-Y, Rennert PD, Gray GS,Gribben JG, Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 1995;2:523-532.
30. Liu L, Kuchroo VK, Weiner HL: B7.2 but not B7.1 costimulation is required for the induction of low dose oral tolerance. FASEB 1998;12:A3466.
31. Desvinges C, Bour H, Nicolas JF, Kaiserlian D: Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility complex class II-deficient mice and in CD4+ T cell-depleted mice. Eur J Immunol 1996;26:1756-1761.
32. Gonnella P, Slavin A, Garcia G, Liu L, Weiner HL: Absence of low-dose oral tolerance in B cell deficient μ mice. FASEB 1998;12:A3476.
33. Komagata Y, Liu LM, Weiner HL: B cells are important for the production of active TGF-β. FASEB 1998;12:A1795.
34. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-1356.
35. Whitacre CC, Gienapp IE, Orosz CG, Bitar D: Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991;147:2155-2163.
36. Melamed D, Friedman A: Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol 1993;23:935-942.
37. Van Houten N, Blake SF: Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J Immunol 1996;157:1337-1341.
38. Chen Y, Inobe J-i, Marks R, Gonnella P, Kuchroo VK, Weiner HL: Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-180.
39. Marth T, Strober E, Kelsall BL: High dose oral tolerance in ovalbumin TCR-transgenic mice: Systemic neutralization of IL-12 augments TGF-beta secretion and T cell apoptosis. J Immunol 1996;157:2348-2357.
40. Santos LMB, Al-Sabbagh A, Londono A, Weiner HL: Oral tolerance to myelin basic protein induces regulatory TGF-β-secreting T cells in Peyer's patches of SJL mice. Cell Immunol 1994;157:439-447.
41. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
42. Chen Y, Inobe J-i, Weiner HL: Induction of oral tolerance to myelin basic protein in CD-8 depleted mice: Both CD4+ and CD8+ T cells mediate active suppression. J Immunol 1995;156:910-916.
43. Weiner HL, Inobe J-i, Kuchroo VK, Chen Y: Induction and characterization of TGF-β secreting cells. FASEB 1996;10:A1444.
44. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol Today 1996;17:138-146.
45. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL: A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4+ T cells. J Exp Med 1996;183:2669-2674.
46. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA: Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98: 70-77.
47. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, deVries JE, Roncarolo MC: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
48. Mowat AM, Steel M, Worthy EA, Kewin PJ, Garside P: Inactivation of Th1 and Th2 cells by feeding ovalbumin. Ann NY Acad Sci 1996;778:122-132.
49. Melamed D, Fishman-Lobell J, Uni Z, Weiner HL, Friedman A: Peripheral tolerance of the Th2 lymphocytes induced by continuous feeding of ovalbumin. Int Immunol 1996;8:717-724.
50. van Halteren AG, van der Cammen MJ, Cooper D, Savelkoul HF, Kraal G, Holt PG: Regulation of antigen-specific IgE, IgG1, and mast cell responses to ingested allergen by mucosal tolerance induction. J Immunol 1997;159:3009-3015.
51. Miller A, Lider O, Weiner HL: Antigen-driven bystander suppression following oral administration of antigens. J Exp Med 1991;174:791-798.
52. Zivny JH, Russell MW, Vu HL, Moldoveanu J, Mestecky J, Elson CO: Multiple mechanisms of oral tolerance to food antigens in humans. FASEB J 1996;10:A1116.
53. McCarron R, Fallis R, McFarlin D: Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1990;29:73-79.
54. Lehmann P, Forsthuber T, Miller A, Sercarz E: Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155.
55. Cross AH, Tuohy VK, Raine CS: Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination. Cell Immunol 1993;146:261-270.
56. Kaufman DI, Clare-Salzler M, Tian J, Forsthuber T, Ting GSP, Robinson P, Atkinson MA, Sercaz EE, Tobin AJ, Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid dccarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72.
57. Tisch R, Yang X-D, Singer SM, Liblau RS, Fugger L, McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366:72-75.
58. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA,Ben-Nun A: Reactivity to myelin antigens in multiple sclerosis: Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993;92:2602-2608.
59. Zhang J, Markovic S, Raus J, Lacet B, Weiner HL, Hafler DA: Increased frequency of IL-2 responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1993;179:973-984.
60. Harrison LC: Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited. Immunol Today 1992;13:348-352.
61. Seder RA, Marth T, Sieve MC, Strober W, Letterio JJ, Roberts AB, Kelsall B: Factors involved in the differentiation of TGF-β-producing cells from naive CD4+ T cells: IL-4 and IFN-γ have opposing effects, while TGF-β positively regulates its own production. J Immunol 1998; in press.
62. Slavin AJ, Maron R, Garcia G, Gonnella P, Weiner HL: Oral administration of IL-4 and IL-10 enhance the induction of low dose oral tolerance. FASEB 1998; in press.
63. Zhang Z, Michael JG: Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment. J Immunol 1990;144:4163-4165.
64. Rizzo LV, Miller-Rivero NE, Chan C-C, Wiggert B, Nussenblatt RB, Caspi RR: Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 1994;94:1668-1672.
65. Khoury SJ, Lider O, Al-Sabbagh A, Weiner HL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell Immunol 1990;131:302-310.
66. Nelson PA, Akselband Y, Dearborn S, Al-Sabbagh A, Tian ZJ, Gonnella P, Zamvil S, Chen Y, Weiner HL: Effect of oral beta interferon on subsequent immune responsiveness. Oral tolerance: Mechanisms and applications. Ann NY Acad Sci 1996;778:145-155.
67. Elson CO, Ealding W: Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984;133:2892-2897.
68. Sun J-B, Holmgren C, Czerkinsky C: Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994; 91:10795-10799.
69. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C: Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996;93:7196-7201.
70. Bergerot I, Fioix C, Peterson J, Moulin V, Rask C, Fabien N, Lindblad M, Mayer A, Czerkinsky C, Homgren J, Thivolet C: A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:4610-4614.
71. Ma D, Mellon J, Niederkorn JY: Oral administration as a strategy for enhancing corneal allograft survival. Br J Ophthalmol 1997;81:778-784.
72. Karpus WJ, Kennedy KJ, Kunkel SL, Lukacs NW: Monocyte protein-1 regulates oral tolerance induction by inhibition of Th1-related cytokines. J Exp Med 1998; in press.
73. Elson CO, Tomasi M, Dertzbaugh MT, Thaggard G, Hunter R, Weaver C: Oral antigen delivery by way of a multiple emulsion system enhances oral tolerance. Oral tolerance: Mechanisms and applications. Ann NY Acad Sci 1996;778:156-162.
74. Ke Y, Pearce K, Lake JP, Ziegler HK, Kapp JA: γδ T lymphocytes regulate the induction and maintaince of oral tolerance. J Immunol 1997;158:3610-3618.
75. Spahn TW, Weiner HL: γδ T cells are necessary for low dose but not high dose oral tolerance. FASEB 1998;12:3464.
76. Bitar DM, Whitacre CC: Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol 1988;112:364-370.
77. Javed NH, Gienapp IE, Cox KL, Whitacre CC: Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J Immunol 1995;155:1599-1605.
78. Lider O, Santos LMB, Lee CSY, Higgins PJ, Weiner HL: Suppression of experimental allergic encephalomyelitis by oral administration of myelin basic protein. II. Suppression of disease and in vitro immune responses is mediated by antigen-specific CD8+ T lymphocytes. J Immunol 1989; 142:748-752.
79. Miller A, Al-Sabbagh A, Santos L, Das MP, Weiner HL: Epitopes of myelin basic protein that trigger TGF-β release following oral tolerization are distinct from encephalitogenic epitopes and mediate epitope driven bystander suppression. J Immunol 1993;151:7307-7315.
80. Khoury SJ, Hancock WW, Weiner HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis as associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-1364.
81. Higgins P, Weiner HL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988;140:440-445.
82. Brod SA, Al-Sabbagh A, Sobel RA, Hafler DA, Weiner HL: Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens. IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. Ann Neurol 1991;29:615-622.
83. Meyer AL, Benson JM, Gienapp IE, Cox KL, Whitacre CC: Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol 1996;157:4230-4238.
84. Al-Sabbagh AM, Goad MEP, Weiner HL, Nelson PA: Decreased CNS inflammation and absence of clinical exerbation of disease after six months oral administration of bovine myelin in diseased SJL/J mice with chronic relapsing experimental autoimmune encephalomyelitis. J Neurol Res 1996; 45:424-429.
85. Chen Y, Inobe J-I, Kuchroo VK, Baron JL, Janeway CA, Weiner HL: Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996;93:388-391.
86. Metzler N, Wraith DC: Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int Immunol 1993;5:1159-1165.
87. Thompson HS, Staines NA: Suppression of collagen-induced arthritis with pregastrically or intravenously administered type II collagen. Agents & Actions 1986;19:318-319.
88. Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbeke FJ: Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83:7443-7446.
89. Thompson HSG, Harper N, Bevan DJ, Staines NA: Suppression of collagen induced arthritis by oral administration of type II collagen: Changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993;16:189-199.
90. Zhang JZ, Lee CSY, Lider O, Weiner HL: Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990;145:2489-2493.
91. Thompson SJ, Thompson, HSG, Harper N, Day MJ, Coad AJ, Elson CJ, Staines NA: Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology 1993;79: 152-157.
92. Yoshino S, Quattrocchi E, Weiner HL: Oral administration of type II collagen suppresses antigen-induced arthritis in lewis rats. Arthritis Rheum 1995;38:1092-1096.
93. Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS: Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J Immunol 1995;155: 3653-3659.
94. Staines NA, Harper N, Ward FJ, Malmström V, Holmdahl R, Bansal S: Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 1996;103:368-375.
95. Myers LK, Seyer JM, Stuart JM, Kang AH: Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 1997;90:161-164.
96. Prakken BJ, van der Zee R, Anderton SM, van Kooten PJS, Kuis W, van Eden W: Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA 1997;94:3284-3289.
97. Gregerson D, Obritsch W, Donoso L: Suppression and clonal anergy play roles in oral tolerance and EAU. Invest Ophthalmol Vis Sci 1993;34(suppl):902.
98. Nussenblatt RB, Caspi RR, Mahdi R, Chan CC, Roberge F, Lider O, Weiner HL: Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990;144:1689-1695.
99. Thurau SR, Caspi RR, Chan CC, Weiner HL, Nussenblatt RB: Immunological suppression of experimental autoimmune uveitis. Fortscher Opthalmol 1991;88:404-407.
100. Singh VK, Kalra HK, Yamaki K, Shinohara T: Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment and a cross-reactive homologous peptide. Cell Immunol 1992;139:81-90.
101. Vrabec TR, Gregerson DS, Dua HS, Donoso LA: Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides. Autoimmunity 1992;12:175-184.
102. Wildner G, Thurau SR: Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: A clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994;24:2579-2585.
103. Wildner G, Thurau SR: Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Eur J Immunol 1995;25:1292-1297.
104. Thurau S, Chan C-C, Nussenblatt R, Caspi R: Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): Induction of protective tolerance in primed animals. Clin Exp Immunol 1997;109:370-376.
105. Thurau SR, Diedrichs-Mohring M, Fricke H, Arbogast S, Wildner G: Molecular mimicry as a therapeutic approach for an autoimmune disease: Oral treatment of uveitis-patients with an MHC-peptide crossreactive with autoantigen - first results. Immunol Lett 1997;57:193-201.
106. Ma C-G, Zhang G-X, Xiao B-G, Link J, Olsson T, Link H: Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol 1995;58: 51-60.
107. Wang H-M, Smith KA: The interleukin-2 receptor: Functional consequences of its bimolecular structure. J Exp Med 1987;166:1055.
108. Wang Z-Y, Qiao J, Link H: Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993;44:209-214.
109. Wang ZY, Qiao J, Melms A, Link H: T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1993;152:394-404.
110. Wang ZY, Link H, Ljungdahl Å, Höjeberg B, Link J, He B, Qiao J, Melms A, Olsson T: Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1994;157:353-368.
111. Wang Z-Y, He B, Qiao J, Link H: Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetylcholine receptor and myelin basic protein: Double tolerance. J Neuroimmunol 1995;63:79-86.
112. Okumura S, McIntosh K, Drachman DB: Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis. Ann Neurol 1994;36:704-713.
113. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W: Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996;183: 2605-2616.
114. Zhang JA, Davidson L, Eisenbarth G, Weiner HL: Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991;88:10252-10256.
115. Bergerot J, Fabien N, Maguer V, Thivolet C: Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun 1994;7:655-663.
116. Hancock WW, Polanski M, Zhang ZJ, Blogg N, Weiner HL: Suppression of insulitis in NOD mice by oral insulin administration is associated with selective expression of IL-4, IL-10, TGF-β and prostaglandin-E. Am J Pathol 1995;147:1193-1199.
117. Harrison LC, Collier-Dempsey M, Kramer DR, Takahashi K: Aerosol insulin induces regulatory CD8 γδ T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996;184;2167-2174.
118. Daniel D, Wegmann DR: Protection of nonobese diabetic mice from diabetics by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996;93:956-960.
119. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996;183:1561-1567.
120. Blanas E, Carbone FR, Allison J, Miller JFAP, Heath WR: Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996;274:1707-1709.
121. von Herrath MG, Dyrberg T, Oldstone MBA: Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996;98:1324-1331.
122. Polanski M, Blogg NS, Zhang J, Weiner HL: Oral administration of the immunodominant B-chain of insulin suppresses diabetes in NOD mice and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997;10:339-346.
123. Ma SW, Zhao DL, Yin ZQ, Mukherjee R, Singh B, Qin HY, Stiller CR, Jevnikar AM: Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med 1997;3: 793-796.
124. Sayegh MH, Zhang ZJ, Hancock WW, Kwok CA, Carpenter CB, Weiner HL: Down-regulation of the immune response to histocompatibility antigen and prevention of sensitization by skin allografts by orally administered alloantigen. Transplant 1992;53:163-166.
125. Sayegh MH, Khoury SJ, Hancock WH, Weiner HL, Carpenter CB: Induction of immunity and oral tolerance with polymorphic class II major histocompatability complex allopeptides in the rat. Proc Natl Acad Sci USA 1992;89:7762-7766.
126. Hancock W, Sayegh M, Kwok C, Weiner H, Carpenter C: Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplant 1993; 55:1112-1118.
127. He YG, Mellon J, Niederkorn JY: The effect of oral immunization on corneal allograft survival. Transplant 1996;61:920-926.
128. Peterson KE, Braley-Mullen H: Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyroglobulin. Cell Immunol 1995;166:123-130.
129. Guimaraes VC, Quintans J, Fisfalen M-E, Straus FH, Wilhelm K, Medeiros-Neto GA, DeGroot LJ: Suppression of experimental autoimmune thyroiditis by oral administration of thyroglobulin. Endocrinology1995;136:3353-3359.
130. Guimaraes VC, Quintans J, Fisfalen ME, Straus FH, Fields PE, Neto GM, DeGroot LJ: Immunosuppression of thyroiditis. Endocrinology 1995;137:2199-2204.
131. Hoyne GF, Callow MG, Kuo MC, Thomas WR: Inhibition of T-cell responses by feeding peptides containing major and cryptic epitopes: Studies with the Der p I allergen. Immunology 1994;83: 190-195.
132. Ilan Y, Prakash R, Davidson A, Jona V, Droguett G, Horwitz M, Chowdhury NR, Chowdhury JR: Oral tolerization to adenoviral antigens permit long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997;99:1098-1106.
133. Lowney ED: Immunologic unresponsiveness to a contact sensitizer in man. J Invest Dermatol 1968; 51:411-417.
134. Waldo FB, Van Den Wall Bake AWL, Mestecky J, Husby S: Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol 1994;72:30-34.
135. Barnett ML, Kremer JM, St. Clair EW, Clegg DO, Furst D, Weisman M, Fletcher MJF, Lavin PT, Finger E, Morales A, Le CH, Trentham DE: Treatment of rheumatoid arthritis with oral type II Collagen: Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998; 41:290-297.
136. Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, Braun J, Zink A, Mitchison NA: Oral type II collagen treatment in early rheumatoid arthritis. Arthritis Rheum 1996;39:41-51.
137. Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996;39:623-628.
138. Nussenblatt RB, Gery I, Weiner HL, Ferris F, Shiloach J, Ramaley N, Perry C, Caspi R, Hafler DA, Foster S, Whitcup SM: Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial. Am J Ophthal 1997;123:583-592.
139. Coutant R, Zeidler A, Rappaport R, Schatz D, Schwanz S, Raskin P, Rogers D, Bode B, Crockett S, Marks J, Deeb L, Chalew S, MacLaren N: Oral insulin therapy in newly-diagnosed immune mediated (type I) diabetes. Preliminary analysis of a randomized double blind placebo controlled study. Diabetes 1998;47(suppl 1):A97.
140. Bagot M, Charue D, Flechet ML, Terki N, Toma A, Revuz J: Oral desensitization in nickel allergy induces a decrease in nickel-specific T-cells. Eur J Dermatol 1995;5:614-617.
141. Miller A, Lider O, Al-Sabbagh A, Weiner H: Suppression of experimental autoimmune encephalomy-elitis by oral administration of myelin basic protein. V. Hierarchy of suppression by myelin basic protein from different species. J Neuroimmunol 1992;39:243-250.
142. Terato K, Xiu JY, Miyahara H, Cremer MA, Griffiths MM: Induction of chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and escherichia coli lipopolysaccharide. Br J Rheumatol 1996;35:1-11.
143. Miller A, Lider O, Abramsky O, Weiner HL: Orally administered MBP in noenates primes for immune responses and enhances EAE in adult animals. Eur J Immunol 1994;24:1026-1032.